Why Intellia Therapeutics, Inc. Stock Lost 19.2% in March [The Motley Fool]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: The Motley Fool
The gene-editing company's stock hit a lifetime high last month but sold off on weaker-than-expected earnings results. Keith Noonan ( TMFNoons ) Apr 13, 2018 at 7:34AM What happened Intellia Therapeutics ( NASDAQ:NTLA ) stock lost 19.2% of its value in March, according to data provided by S&P Global Market Intelligence . Data source: NTLA data by YCharts. The bulk of the stock's movement last month occurred after the company posted fourth-quarter earnings results on March 14 and delivered results that fell short of the market's expectations. Image source: Getty Images. So what Intellia shares rose early in the month, hitting a new lifetime high as the market reacted to favorable ratings coverage and bid the stock up in anticipation of its fourth-quarter earnings report. Barclays Capital raised its price target on the stock fr
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Rob Lauzon's Top Picks: March 25, 2024 [BNN Bloomberg (Canada)]BNN Bloomberg
- Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyGlobeNewswire
- Is Intellia Therapeutics Stock a Buy Now? [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/22/24 - Beat
NTLA
Sec Filings
- 3/22/24 - Form 8-K
- 3/5/24 - Form 4
- 3/5/24 - Form 4
- NTLA's page on the SEC website